NASDAQ:MNOV - MediciNova Stock Price, Forecast & News

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

MediciNova, Inc. (NASDAQ:MNOV) posted its earnings results on Thursday, October, 29th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.04. View MediciNova's Earnings History.

MediciNova is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for MediciNova.

1 brokers have issued 1-year price objectives for MediciNova's shares. Their forecasts range from $22.00 to $22.00. On average, they expect MediciNova's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 277.4% from the stock's current price. View Analyst Price Targets for MediciNova.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MediciNova.

News stories about MNOV stock have trended very negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MediciNova earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for MediciNova.

MediciNova saw a drop in short interest during the month of January. As of January 15th, there was short interest totalling 2,940,000 shares, a drop of 8.1% from the December 31st total of 3,200,000 shares. Based on an average trading volume of 107,700 shares, the short-interest ratio is presently 27.3 days. Currently, 8.0% of the company's shares are sold short. View MediciNova's Current Options Chain.

Some companies that are related to MediciNova include NextCure (NXTC), Portola Pharmaceuticals (PTLA), Myovant Sciences (MYOV), Opko Health (OPK), Akebia Therapeutics (AKBA), Enanta Pharmaceuticals (ENTA), Dermira (DERM), ImmunoGen (IMGN), Odonate Therapeutics (ODT), Applied Therapeutics (APLT), Kiniksa Pharmaceuticals (KNSA), Karyopharm Therapeutics (KPTI), Gossamer Bio (GOSS), Achillion Pharmaceuticals (ACHN) and I-Mab (ARQT).

Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Novavax (NVAX), Progenics Pharmaceuticals (PGNX), Amicus Therapeutics (FOLD), Geron (GERN), NovaBay Pharmaceuticals (NBY), Cytokinetics (CYTK), Immunomedics (IMMU), Inovio Pharmaceuticals (INO), Opko Health (OPK) and Pieris Pharmaceuticals (PIRS).

MediciNova's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (1.73%), Bank of New York Mellon Corp (0.36%), Charles Schwab Investment Management Inc. (0.23%), California Public Employees Retirement System (0.19%), Goldman Sachs Group Inc. (0.13%) and UBS Group AG (0.12%). View Institutional Ownership Trends for MediciNova.

MNOV stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund. View Insider Buying and Selling for MediciNova.

MNOV stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, UBS Group AG, California Public Employees Retirement System, Barclays PLC, Marshall Wace LLP, Bank of America Corp DE, State Street Corp and Goldman Sachs Group Inc.. View Insider Buying and Selling for MediciNova.

Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MNOV stock can currently be purchased for approximately $5.83.

MediciNova has a market capitalization of $255.60 million. The biopharmaceutical company earns $-12,940,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. MediciNova employs 9 workers across the globe.View Additional Information About MediciNova.

The official website for MediciNova is http://medicinova.com/.

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]